MDimune Inc., a cell-derived vesicle (CDVs)-based therapeutics company with BioDrone® platform technology, announced on April 30th, 2020, the signature of a research collaboration agreement with Paracelsus Medical University (PMU, Salzburg, Austria). PMU will bring their experience to further the company’s global development goals.
International Online Press Reactions:
- BioSpace "MDimune Signed a Research Collaboration Agreement with Paracelsus Medical University for EV Therapeutics Development" [see homepage]
- Stem Cell Clinic "MDimune Signed a Research Collaboration Agreement with Paracelsus Medical University for EV Therapeutics Development – BioSpace" [see homepage]
- News Wire "MDimue signs a Joint R&D Agreement with Paracelsus Medical University in Austria" [see homepage]
- Press Korea "MDimune signs a joint R&D agreement with Paracelsus Medical University in Austria" [see homepage]
- Start Up Today "New drug development company MDimune, clinical development speed of incurable disease treatment using extruded exosomes" [see homepage]
- Stem Cells "MDimune Signed a Research Collaboration Agreement with Paracelsus Medical University for EV Therapeutics Development – BioSpace" [see homepage]
- Exosome RNA "MDimune to Collaborate with Paracelsus Medical University for EV Therapeutics Development" [see homepage]
- Pharm Stock "MDimune Signs Research and Development Agreement with Paracelsus Medical University in Austria" [see homepage]
- BioInformant "MDimune Collaborating with Paracelsus Medical University for EV Therapeutics" [see homepage]
Social Media:
- YouTube "MDimune und die Paracelsus Universität arbeiten zusammen an der Entwicklung von EV-Therapeutika" [weiter zum Beitrag]
